ArticleCell death & disease2021

MEDAG enhances breast cancer progression and reduces epirubicin sensitivity through the AKT/AMPK/mTOR pathway.

Zhiyu Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.